Granules India liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
7.05×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.80×1.80×1.56×1.40×1.42×
1.00×1.00×0.88×0.77×0.79×
880880466381292
1,6761,6761,112823761
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GRANULES₹837.35

Granules India Ltd.

· Pharma & Health
₹ CrorePeersAUROPHARMAIPCALABAARTIDRUGSERISINDGNEMCUREJUBLPHARMACONCORDBIOMcap ₹20,750 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Altman Z-Score (Other Equity as RE)————7.05
Current Ratio1.421.401.561.801.80
Quick Ratio0.790.770.881.001.00
Cash, Equiv & ST Investments291.6381.1466.1880.2880.2
Working Capital760.6822.81,112.31,675.61,675.6
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.